[Botulinum toxin in nonneurogenic bladder dysfunction]

Urologe A. 2009 Mar;48(3):233-44. doi: 10.1007/s00120-008-1918-8.
[Article in German]

Abstract

Nonneurogenic overactive bladder with or without detrusor overactivity and/or incontinence is a bothersome symptom for many people. Until a few years ago, it could be treated only with anticholinergic drugs or invasive surgery. Intradetrusor injection with botulinum toxin type A is a minimally invasive alternative therapy option for patients who do not respond to or tolerate anticholinergic treatment. This literature overview summarises the relevant articles on this topic over the last 6 years and provides information on the efficacy, adverse events, currently used dosages, and injection techniques. Overall, a favourable initial efficacy has been observed starting around day 4 after injection and can last up to approximately 31 weeks. Depending on the dose, however, elevated postvoid residual volumes should be anticipated and might require clean intermittent self-catheterisation. The use of botulinum toxin in the urinary bladder is still considered off-label.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Botulinum Toxins / administration & dosage*
  • Botulinum Toxins / adverse effects*
  • Dose-Response Relationship, Drug
  • Humans
  • Urinary Bladder, Neurogenic
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Bladder, Overactive / prevention & control*

Substances

  • Botulinum Toxins